Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

58.13
+0.98001.71%
Post-market: 58.130.00000.00%19:34 EST
Volume:1.64M
Turnover:95.42M
Market Cap:11.17B
PE:21.68
High:58.43
Open:57.26
Low:57.26
Close:57.15
52wk High:73.51
52wk Low:50.76
Shares:192.11M
Float Shares:178.10M
Volume Ratio:0.92
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.68
EPS(LYR):2.21
ROE:9.07%
ROA:6.15%
PB:1.84
PE(LYR):26.34

Loading ...

BioMarin Pharmaceutical Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Yesterday

BioMarin price target lowered to $84 from $122 at Piper Sandler

TIPRANKS
·
Feb 06

U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren

Reuters
·
Feb 06

Biomarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

THOMSON REUTERS
·
Jan 30

Biomarin Pharmaceutical Inc - Completes Syndication of $2 Bln Term Loan "B" Facility

THOMSON REUTERS
·
Jan 30

BioMarin Weighs Amicus Deal And Billions In New Debt Financing

Simply Wall St.
·
Jan 29

Biomarin Pharmaceutical Inc - Estimates $3.2 Bln in Total Revenues for 2025 - SEC Filing

THOMSON REUTERS
·
Jan 26

Biomarin Pharmaceutical Inc FY2025 REV View $3.18 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 26

BRIEF-BioMarin Announces Proposed Private Offering Of Senior Notes And Syndication Of New Senior Secured Term Loan Facility

Reuters
·
Jan 26

BioMarin Pharmaceutical Launches $3.65 Billion Debt Offering for Amicus Acquisition

Reuters
·
Jan 26

Biomarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

THOMSON REUTERS
·
Jan 26

Biomarin Pharmaceutical Inc - to Offer $850 Mln Senior Unsecured Notes Due 2034

THOMSON REUTERS
·
Jan 26

Biomarin Pharmaceutical Inc - Launches $2 Bln Senior Secured Term Loan Facility

THOMSON REUTERS
·
Jan 26

Biomarin Pharmaceutical Inc - to Use Notes Offering Proceeds to Fund Amicus Acquisition

THOMSON REUTERS
·
Jan 26

BioMarin Pharmaceutical Inc. Files Initial Beneficial Ownership Statement for Rashmi Virendra Ramchandani, VP and Chief Accounting Officer

Reuters
·
Jan 23

Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84

MT Newswires Live
·
Jan 20

BioMarin Pharmaceutical Raised to Buy From Hold by Canaccord Genuity

Dow Jones
·
Jan 20

BioMarin upgraded to Buy from Hold at Canaccord

TIPRANKS
·
Jan 20

U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft

Reuters
·
Jan 20

Biomarin Pharmaceutical Inc : Canaccord Genuity Raises to Buy From Hold; Raises Target Price to $98 From $84

THOMSON REUTERS
·
Jan 20